4 AUGUST NEW ZEALAND GAZETTE 2477

Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name
| | | (if any)
Danthron 75 mg, poloxamer 188, 1000 mg per 5 ml | Suspension (oral) | Regent Laboratories Limited, North Acton, London, England and Universal Products Limited, Lytham, Lancashire, England | Codalax Forte

This medicine may only be used for the prevention of, or the treatment of:

1. Opiate induced constipation.
2. Constipation in the elderly.
   Dated this 25th day of July 1994.

D. SMYTH, Acting Director-General of Health, pursuant to delegation given by the Minister of Health on the 25th day of June 1993.

go5765

Consent to the Distribution of New Medicines

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicine set out in the Schedule hereto:

Schedule

Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name
| | | (if any)
● Budesonide 50 mcg, 100 mcg | Suspension for spray (nasal spray) | Pacific Pharmaceuticals Limited, Mount Wellington, Auckland | Butacort Aqueous
Dopamine hydrochloride 800 mg, 1600 mg, 3200 mg, 6400 mg | Solution for infusion | Baxter Healthcare Corporation, Jayuya, Puerto Rico | Dopamine Hydrochloride in 5% Dextrose injection
Oestradiol delivery rate: 50 mcg/day, 100 mcg/day | Transdermal patch | 3M Pharmaceuticals Inc., Northridge, California, United States of America and 3M Pharmaceuticals Inc., Saint Paul, Minnesota, United States of America | Femtran Transdermal Oestradiol Delivery System
Nitroglycerine 10 mg, 20 mg, 40 mg per 100 ml (as diluted nitroglycerine with propylene glycol) in 250 ml | Injection | Baxter Healthcare Corporation, Cleveland, Mississippi, United States of America | Nitroglycerine in 5% Dextrose
Gabapentin 100 mg, 300 mg, 400 mg | Capsules | Goedecke AG, Freiburg, Germany | Neurontin

Dated this 25th day of July 1994.

D. SMYTH, Acting Director-General of Health, pursuant to delegation given by the Minister of Health on the 25th day of June 1993.

go5766

Consent to the Distribution of Changed Medicines

Pursuant to section 24 (5) of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines set out in the Schedule hereto:

Schedule

Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name
| | | (if any)
Minocycline (as the hydrochloride) 100 mg | Capsule (modified release) | Cyanamid of Great Britain Limited, Gosport, Hampshire, England | Minomycin MR
Morphine sulphate 10 mg, 20 mg | Tablet (immediate release) | Bard Pharmaceuticals Limited, Cambridge, England | Sevredol
Ceftriaxone 250 mg, 500 mg, 1 g (as ceftriaxone disodium) (with 1% Lidocaine diluent) | Powder for reconstitution for IM injection | F Hoffmann-La Roche Limited, Basle, Switzerland | Rocephin
Ceftriaxone 250 mg, 500 mg, 1 g (as ceftriaxone disodium) (with sterile water diluent) | Powder for reconstitution for IV injection | F Hoffmann-La Roche Limited, Basle, Switzerland | Rocephin
Ceftriaxone 2 g (as ceftriaxone disodium) | Powder for reconstitution for infusion | F Hoffmann-La Roche Limited, Basle, Switzerland | Rocephin
Bleomycin 15 mg (as bleomycin sulphate) | Injection (vial) | Nippon Kayaku Co Limited, Chiyoda-Ku, Tokyo, Japan | Blenoxane